Three independent discounted-cash-flow-style models value Catalyst Pharmaceuticals Inc every trading day. 0 of 3 currently price CPRX above its market price.
| Free Cash Flow model | $-20.45 |
| Excess Profit model | $23.08 |
| Residual Earnings model | $4.52 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +21.3% |
| Net debt / EBITDA | -2.6× |
| Gross margin | +86.0% |
| Revenue CAGR | — |
| Cash conversion | 1.5× |
| Dividend yield | — |
| Buyback yield | -12.8% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open CPRX in StockKitty